{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T03:47:40Z","timestamp":1781668060067,"version":"3.54.5"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"Supplement_3","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>For a long time, a prognostic and therapeutic fatalism accompanied even the most motivated clinicians when they had to deal with a progressive decline in renal function; the modest successes were nullified by an increasingly aggressive syndrome whose therapy had remained the same for more than 30 years. In the meantime, the increased understanding of the physiopathological mechanisms connected to it had not been accompanied by an equal development of drugs capable of counteracting it, and this, also due to the progressive aging of the population, had rapidly made \u2018chronic kidney disease\u2019 (CKD) a problem of World Public Health due to its incidence, prevalence, and exponentially increasing costs in every part of the world. The progressive reduction of glomerular filtration rate, as has been known for some time, is accompanied by an increase in cardiovascular risk, understood as fatal and non-fatal heart attack, stroke, heart failure, and mortality. Therefore, every effort must be aimed at preventing or slowing the decline of renal function to reduce not only critical renal events (the need for dialysis or transplant among the most feared) but also the incidence of cardiovascular events. Since the disease is asymptomatic for a long time (it is often detected occasionally and with culpable delay), it is essential to make a correct and early assessment of renal function with appropriate methods. Once CKD was identified, clinicians, to slow its progression, could rely for a long time only on strict control of those risk factors most responsible for worsening it, such as diabetes and its complications, on the optimization of high blood pressure values and the mandatory use of drugs blocking the renin\u2013angiotensin\u2013aldosterone system, particularly in the presence of albuminuria. This strategy has proven to be only partially effective over time, and most patients still showed a progressive worsening of renal function. Only in the last few years have we had access to two classes of innovative drugs, such as gliflozins and incretins, that have imposed themselves on the therapeutic scene because they have shown that they can slow the progression of CKD, first in patients with Type 2 diabetes and subsequently in patients with CKD regardless of the presence or absence of diabetes. Unexpectedly and convincingly, they have also shown a significant impact on cardiovascular prognosis. Initially antidiabetic drugs, their efficacy has forced the reviewers of both cardiology and nephrology guidelines to indicate them among the drugs to use. Lately, the class of mineralocorticoid receptor antagonist drugs has been enriched by finerenone. This molecule has favourable pharmacokinetic characteristics compared with previous medications of the same class and tested in Phase 3, randomized, placebo-controlled trials (FIDELIO-DKD and FIGARO-DKD) which has been shown to significantly reduce the risk of cardiovascular and renal disease in diabetic patients compared with placebo.<\/jats:p>","DOI":"10.1093\/eurheartjsupp\/suaf019","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:24:43Z","timestamp":1744813483000},"page":"iii73-iii78","source":"Crossref","is-referenced-by-count":2,"title":["Preserving renal function: gliflozins, GLP1 agonists, and antialdosterones"],"prefix":"10.1093","volume":"27","author":[{"given":"Gennaro","family":"Cice","sequence":"first","affiliation":[{"name":"UOC of Cardiology, Policlinico Casilino, via Casilina , 1049, 00169 Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"2025041610242918400_suaf019-B1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2019.09.003","article-title":"US renal data system 2019 annual data report: epidemiology of kidney disease in the United States","volume":"75","author":"Saran","year":"2020","journal-title":"Am J Kidney disease"},{"key":"2025041610242918400_suaf019-B2","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Chronic Kidney Disease Prognosis Consortium","year":"2010","journal-title":"Lancet"},{"key":"2025041610242918400_suaf019-B3","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2025041610242918400_suaf019-B4","first-page":"1","article-title":"Kidney disease: improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2025041610242918400_suaf019-B5","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"2025041610242918400_suaf019-B6","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"SPRINT Research Group","year":"2015","journal-title":"N Engl J Med"},{"key":"2025041610242918400_suaf019-B7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(05)71082-5","article-title":"Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial","volume":"365","author":"Ruggenenti","year":"2005","journal-title":"Lancet"},{"key":"2025041610242918400_suaf019-B8","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"2025041610242918400_suaf019-B9","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.2215\/CJN.09110914","article-title":"Meta-analysis of the effect of dietary sodium restriction with or without concomitant renin-angiotensin-aldosterone system-inhibiting treatment on albuminuria","volume":"10","author":"D\u2019Elia","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025041610242918400_suaf019-B10","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1097\/HJH.0000000000002187","article-title":"Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Alexandrou","year":"2019","journal-title":"J Hypertens"},{"key":"2025041610242918400_suaf019-B11","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025041610242918400_suaf019-B12","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"2025041610242918400_suaf019-B13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S2213-8587(17)30104-3","article-title":"Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials","volume":"5","author":"Zougas","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025041610242918400_suaf019-B14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/dc22-S009","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","journal-title":"Diabetes Care"},{"key":"2025041610242918400_suaf019-B15","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2025041610242918400_suaf019-B16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2025041610242918400_suaf019-B17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025041610242918400_suaf019-B18","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIRCULATIONAHA.118.038868","article-title":"Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus","volume":"139","author":"Zelniker","year":"2019","journal-title":"Circulation"},{"key":"2025041610242918400_suaf019-B19","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025041610242918400_suaf019-B20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.amjcard.2022.07.012","article-title":"Benefits of adding glucagon-like peptide 1 receptor agonists to sodium-glucose co-transporter 2 inhibitors in diabetic patients with atherosclerotic disease and heart failure","volume":"181","author":"David Lopez","year":"2022","journal-title":"AMj Cardiol"},{"key":"2025041610242918400_suaf019-B21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"2025041610242918400_suaf019-B22","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpdd.263","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment","volume":"5","author":"Heining","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2025041610242918400_suaf019-B23","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"385","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025041610242918400_suaf019-B24","first-page":"475","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"39","author":"Solomon","year":"2024","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/27\/Supplement_3\/iii73\/62939360\/suaf019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/27\/Supplement_3\/iii73\/62939360\/suaf019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T14:24:47Z","timestamp":1744813487000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/27\/Supplement_3\/iii73\/8114534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":24,"journal-issue":{"issue":"Supplement_3","published-online":{"date-parts":[[2025,4,16]]},"published-print":{"date-parts":[[2025,4,16]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartjsupp\/suaf019","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2025,3]]}}}